Lv3
260 积分 2026-01-12 加入
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
24天前
已完结
Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
24天前
已完结
Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periostin
24天前
已完结
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
24天前
已完结
Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD
24天前
已完结
MASLD, MASH, and the CKM Spectrum
26天前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease
2个月前
已完结
皖公网安备34019202002308
